Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01578772 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease
A Phase 2 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01578772 is a Phase 2 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 17 participants.
The verdict
NCT01578772, a Phase 2 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This research study is to see whether blood vessel function, an early sign of heart disease, improves in HIV-infected men and women who take telmisartan for 12 weeks. The investigators will be looking at how a blood vessel in the arm, called the brachial artery, changes in response to stress before and after taking telmisartan. To determine how well the blood vessel functions, the investigators will be using an ultrasound machine. Telmisartan is not an HIV medication. It is an FDA-approved medication designed to treat blood pressure, but has been shown to improve blood vessel function in HIV-negative people with and without high blood pressure. Telmisartan is made by Boehringer Ingelheim, and this trial is sponsored by The Campbell Foundation.
Interventions
- DRUG Telmisartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01578772
The ClinicalTrials.gov registry entry for NCT01578772 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Telmisartan is the first listed.
NCT01578772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01578772 about?
NCT01578772 is a clinical study titled "A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease". This research study is to see whether blood vessel function, an early sign of heart disease, improves in HIV-infected men and women who take telmisartan for 12 weeks. The investigators will be looking at how a blood vessel in the arm, called the brachial artery, changes in response to stress before ...
What is the current status of trial NCT01578772?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2012-08. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01578772?
The interventions under investigation include: Telmisartan (DRUG).
Who is sponsoring clinical trial NCT01578772?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.